SPRINT Stock Overview
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sprint Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.21 |
| 52 Week High | kr3.28 |
| 52 Week Low | kr0.45 |
| Beta | 0.55 |
| 1 Month Change | -6.05% |
| 3 Month Change | 16.54% |
| 1 Year Change | 104.73% |
| 3 Year Change | -76.00% |
| 5 Year Change | -92.89% |
| Change since IPO | -92.43% |
Recent News & Updates
Shareholder Returns
| SPRINT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -12.8% | 0.1% | -0.6% |
| 1Y | 104.7% | 8.7% | 17.3% |
Return vs Industry: SPRINT exceeded the Swedish Biotechs industry which returned 6.4% over the past year.
Return vs Market: SPRINT exceeded the Swedish Market which returned 17.4% over the past year.
Price Volatility
| SPRINT volatility | |
|---|---|
| SPRINT Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SPRINT's share price has been volatile over the past 3 months.
Volatility Over Time: SPRINT's weekly volatility has decreased from 40% to 14% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 28 | Johan Emilsson | www.sprintbioscience.com |
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes.
Sprint Bioscience AB (publ) Fundamentals Summary
| SPRINT fundamental statistics | |
|---|---|
| Market cap | kr84.62m |
| Earnings (TTM) | kr8.77m |
| Revenue (TTM) | kr68.88m |
9.6x
P/E Ratio1.2x
P/S RatioIs SPRINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRINT income statement (TTM) | |
|---|---|
| Revenue | kr68.88m |
| Cost of Revenue | kr13.63m |
| Gross Profit | kr55.25m |
| Other Expenses | kr46.47m |
| Earnings | kr8.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 80.21% |
| Net Profit Margin | 12.74% |
| Debt/Equity Ratio | 0% |
How did SPRINT perform over the long term?
See historical performance and comparison